Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	9,158	10,369	10,504	6,795	5,988	3,109
Short-Term Investments	1,013	849.2	274.5	729.9	670.7	698.97
Cash & Cash Equivalents	10,171	11,218	10,779	7,525	6,659	3,808
Cash Growth	-2.33%	4.08%	43.24%	13.01%	74.85%	20.20%
Receivables	1,793	1,563	1,442	1,137	885.4	633.52
Inventory	813.1	738.8	460.6	353.1	280.8	167.5
Other Current Assets	511.1	623.7	553.5	545.8	308.3	213.52
Total Current Assets	13,289	14,144	13,235	9,561	8,133	4,823
Property, Plant & Equipment	1,486	1,453	1,456	1,424	1,284	833.28
Long-Term Investments	4,381	2,498	112.2	0	0	0
Goodwill and Intangibles	1,923	1,928	1,692	1,402	1,402	1,402
Other Long-Term Assets	2,839	2,707	1,657	1,045	932.1	1,260
Total Long-Term Assets	10,629	8,586	4,916	3,872	3,618	3,496
Total Assets	23,917	22,730	18,151	13,433	11,752	8,318
Accounts Payable	351.4	364.9	303.9	195	155.1	87.61
Other Current Liabilities	3,445	3,183	2,438	1,947	1,722	1,247
Total Current Liabilities	3,796	3,547	2,742	2,142	1,878	1,335
Long-Term Debt	721.3	724.7	810.3	887.2	889.5	622.87
Other Long-Term Liabilities	853.6	877.7	685.8	303.3	298	275.53
Total Long-Term Liabilities	1,575	1,602	1,496	1,191	1,188	898.39
Total Liabilities	5,371	5,150	4,238	3,333	3,065	2,233
Total Debt	721.3	724.7	810.3	887.2	889.5	622.87
Debt Growth	-8.60%	-10.56%	-8.67%	-0.26%	42.81%	7.10%
Retained Earnings	11,242	10,142	6,523	3,201	858.7	-1,852.98
Comprehensive Income	17.3	-14.3	0.8	15.9	-68.5	-1.97
Shareholders' Equity	18,547	17,580	13,913	10,100	8,687	6,085
Net Cash / Debt	9,450	10,494	9,968	6,638	5,769	3,185
Net Cash / Debt Growth	-1.82%	5.27%	50.18%	15.05%	81.12%	23.15%
Net Cash Per Share	36.19	40.28	38.47	25.54	21.90	12.22
Working Capital	9,493	10,597	10,493	7,419	6,256	3,488
Book Value Per Share	71.83	68.22	54.33	39.19	33.44	23.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).